CA2307826A1 - Amelioration d'activite morphogene - Google Patents

Amelioration d'activite morphogene Download PDF

Info

Publication number
CA2307826A1
CA2307826A1 CA002307826A CA2307826A CA2307826A1 CA 2307826 A1 CA2307826 A1 CA 2307826A1 CA 002307826 A CA002307826 A CA 002307826A CA 2307826 A CA2307826 A CA 2307826A CA 2307826 A1 CA2307826 A1 CA 2307826A1
Authority
CA
Canada
Prior art keywords
xaa
morphogen
res
xaa xaa
leu
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002307826A
Other languages
English (en)
Inventor
Marc F. Charette
David C. Rueger
Dennis Higgins
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Creative Biomolecules Inc
Curis Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Creative Biomolecules Inc, Curis Inc filed Critical Creative Biomolecules Inc
Publication of CA2307826A1 publication Critical patent/CA2307826A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1875—Bone morphogenic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Psychology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La présente invention concerne des procédés et des compositions permettant d'améliorer une activité morphogène chez les mammifères, y compris chez les humains. Ces procédés consistent à administrer une molécule capable de libérer l'inhibition morphogène. Cette molécule peut être administrée seule ou en combinaison avec un morphogène. La présente invention concerne, en outre, des procédés de criblage permettant d'identifier une molécule capable d'améliorer une activité morphogène.
CA002307826A 1997-10-27 1998-10-26 Amelioration d'activite morphogene Abandoned CA2307826A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US6362497P 1997-10-27 1997-10-27
US60/063,624 1997-10-27
PCT/US1998/022655 WO1999021574A2 (fr) 1997-10-27 1998-10-26 Amelioration d'activite morphogene

Publications (1)

Publication Number Publication Date
CA2307826A1 true CA2307826A1 (fr) 1999-05-06

Family

ID=22050440

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002307826A Abandoned CA2307826A1 (fr) 1997-10-27 1998-10-26 Amelioration d'activite morphogene

Country Status (5)

Country Link
EP (1) EP1027059A2 (fr)
JP (1) JP2002506000A (fr)
AU (1) AU1122099A (fr)
CA (1) CA2307826A1 (fr)
WO (1) WO1999021574A2 (fr)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2104678C (fr) 1991-03-11 2002-05-14 Charles M. Cohen Morphogenese induite par des proteines
GB9907461D0 (en) * 1999-03-31 1999-05-26 King S College London Neurite regeneration
US20030170213A1 (en) * 1998-01-23 2003-09-11 Marc F. Charette Methods and compositions for enhancing cognitive function using morphogenic proteins
US6696410B1 (en) 1999-09-27 2004-02-24 Stryker Corporation Compositions and therapeutic methods using morphogenic proteins, hormones and hormone receptors
EP1220909A2 (fr) * 1999-09-27 2002-07-10 Stryker Corporation Compositions et methodes therapeutiques utilisant des proteines morphogeniques, des hormones et des recepteurs d'hormones
DE60132436T2 (de) * 2000-03-30 2008-04-17 Oxford Biomedica (Uk) Ltd. Retinolsäure-rezeptor beta-2 und gentherapievektoren für die behandlung von neurologischen erkrankungen
EP1478384A2 (fr) * 2001-06-11 2004-11-24 Ludwig Institute For Cancer Research Procede pour augmenter la survie de cellules secretant de la dopamine
MXPA05008713A (es) * 2003-02-24 2005-09-20 Chugai Pharmaceutical Co Ltd Agente terapeutico para dano de medula espinal que comprende antagonista de interluceina-6.
AU2005210493B2 (en) 2004-02-02 2009-06-04 Pioneer Hi-Bred International, Inc. AP2 domain transcription factor ODP2 (ovule development protein 2) and methods of use
AU2010339481B2 (en) 2009-12-30 2016-02-04 Pioneer Hi-Bred International, Inc. Methods and compositions for targeted polynucleotide modification
EP3078748B1 (fr) 2009-12-30 2021-08-11 Pioneer Hi-Bred International, Inc. Procédés et compositions pour l'introduction et l'expression régulée de gènes dans des plantes

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6040431A (en) * 1995-06-07 2000-03-21 Stryker Corporation Single chain analogs of the TGF-β superfamily (morphons)
US5834188A (en) * 1995-07-26 1998-11-10 Creative Biomolecule, Inc. Methods and compositions for identifying morphogen analogs
AU709991B2 (en) * 1995-08-14 1999-09-09 Creative Biomolecules, Inc. Binding of osteogenic protein-1 (OP-1) and analogs thereof to the cell surface receptor ALK-1 and analogs thereof

Also Published As

Publication number Publication date
EP1027059A2 (fr) 2000-08-16
AU1122099A (en) 1999-05-17
JP2002506000A (ja) 2002-02-26
WO1999021574A3 (fr) 1999-07-08
WO1999021574A9 (fr) 1999-08-12
WO1999021574A2 (fr) 1999-05-06

Similar Documents

Publication Publication Date Title
US6632618B1 (en) Morphogenic protein-specific cell surface receptors and uses therefor
CA2104678C (fr) Morphogenese induite par des proteines
US6723698B2 (en) Methods and compositions for the treatment of motor neuron injury and neuropathy
US6506729B1 (en) Methods and compositions for the treatment and prevention of Parkinson's disease
US6949505B1 (en) Morphogen-induced dendritic growth
JPH08503198A (ja) Ｏｐ−３誘導形態形成
JP5346657B2 (ja) 組織形態形成および活性を評価するための方法
US20040176292A1 (en) Methods and compositions for enhancing cognitive function using morphogenic proteins
Mitsiadis et al. Patterns of nerve growth factor (NGF), proNGF, and p75 NGF receptor expression in the rat incisor: comparison with expression in the molar
US7147839B2 (en) Methods for evaluating tissue morphogenesis and activity
CA2116560C (fr) Methode de criblage de proteines morphogeniques
CA2307826A1 (fr) Amelioration d'activite morphogene
Wozney et al. Bone morphogenetic proteins
US20070066525A1 (en) Compositions and therapeutic methods using morphogenic proteins
JP2001507354A (ja) 局所的モルフォゲンまたは形態形成処理された筋形成前駆体細胞による哺乳動物心筋層の処置
AU5436798A (en) Morphogen peptide-induced regeneration of sense perceptory tissues
AU635412B2 (en) A method for regulating neuron development and maintenance
CA2371695A1 (fr) Augmentation de fertilite induite par des morphogenes
CA2323078A1 (fr) Compositions pour moduler la differentiation des cellules comprenant un lipide et un morphogene
WO1994006447A2 (fr) Morphogenese induite par la proteine 60a

Legal Events

Date Code Title Description
FZDE Discontinued